<p>(A) C57BL/6 mice were injected subcutaneously with 1×10<sup>6</sup> McgR32 cellsand 8 day later, with MPSSS or PBS intraperitoneally once every two days. Tumor volume was recorded as the mean ± SD and each group contained 3–4 mice and was analyzed by one-way ANOVA for repeated measures data. (B) At the indicated days after tumor cell injection, peripheral blood was taken for MDSC detection by flow cytometry, Quantitative data are expressed as mean ± SD and analyzed by Student's <i>t</i> tests. *<i>P</i><0.05, **<i>P</i><0.01. (C) A representative flow cytometry analysis was shown for the staining of CD11b and Gr1.</p
<p>(A) Rgs2−/− and C57BL/6 wild type mice were injected with 5×10<sup>5</sup> 3LL tumor cells subcut...
<p>Myeloid cells and granulocytic cells from PECs of MOSEC-bearing WT and p47<i><sup>phox−/−</sup></...
<p>A, Tumor incidence from 3 experiments. Equal numbers of sex matched SCID mice were injected s.c. ...
<p><b><i>1A</i></b><i>,</i> representative FACS plots for MDSC in blood, BM, spleen and tumor of 3LL...
<p>(A) [<sup>3</sup>H]-thymidine or (B) CFSE-labeled splenocytes were co-cultured with purified MDSC...
<p>A) Representative quantification of MDSCs. Splenocytes from WT and p47<i><sup>phox−/−</sup></i> m...
<p>(A) FACS-sorted splenic MDSCs from McgR32 tumor-bearing mice with or without MPSSS stimulation we...
<p>Tumor-bearing mice were treated with 10, 25 or 50 mg/kg of mAb AFS98 or PBS, IP, starting from da...
<p>MOSEC tumors were established in C57BL/6 mice for 4 weeks. MSCs, <i>MSC1,</i> or <i>MSC2</i> (1×1...
<p><b>(</b>A) MDSCs as characterized by CD11b+ and GR1+ were gated from splenocytes or tumor samples...
<p>(<b>A</b>) Wt mice were inoculated with 1×10<sup>5</sup> B16-OVA cells and injected with 5×10<sup...
<p>RCAS-Neu breast cancer cells (5×10<sup>5</sup>) in a 50 ml volume were mixed with equal volume of...
<p>BFS1 tumor cells were inoculated subcutaneously after 19 days of either SHC (white bars, n = 7) o...
<p>B16-F10 tumors were established on the flanks of C57BL/6J mice on day 0. Tumors were ablated by P...
<p>Tumour load was assessed by flow cytometry analysis of GFP cells and spleen weight was measured. ...
<p>(A) Rgs2−/− and C57BL/6 wild type mice were injected with 5×10<sup>5</sup> 3LL tumor cells subcut...
<p>Myeloid cells and granulocytic cells from PECs of MOSEC-bearing WT and p47<i><sup>phox−/−</sup></...
<p>A, Tumor incidence from 3 experiments. Equal numbers of sex matched SCID mice were injected s.c. ...
<p><b><i>1A</i></b><i>,</i> representative FACS plots for MDSC in blood, BM, spleen and tumor of 3LL...
<p>(A) [<sup>3</sup>H]-thymidine or (B) CFSE-labeled splenocytes were co-cultured with purified MDSC...
<p>A) Representative quantification of MDSCs. Splenocytes from WT and p47<i><sup>phox−/−</sup></i> m...
<p>(A) FACS-sorted splenic MDSCs from McgR32 tumor-bearing mice with or without MPSSS stimulation we...
<p>Tumor-bearing mice were treated with 10, 25 or 50 mg/kg of mAb AFS98 or PBS, IP, starting from da...
<p>MOSEC tumors were established in C57BL/6 mice for 4 weeks. MSCs, <i>MSC1,</i> or <i>MSC2</i> (1×1...
<p><b>(</b>A) MDSCs as characterized by CD11b+ and GR1+ were gated from splenocytes or tumor samples...
<p>(<b>A</b>) Wt mice were inoculated with 1×10<sup>5</sup> B16-OVA cells and injected with 5×10<sup...
<p>RCAS-Neu breast cancer cells (5×10<sup>5</sup>) in a 50 ml volume were mixed with equal volume of...
<p>BFS1 tumor cells were inoculated subcutaneously after 19 days of either SHC (white bars, n = 7) o...
<p>B16-F10 tumors were established on the flanks of C57BL/6J mice on day 0. Tumors were ablated by P...
<p>Tumour load was assessed by flow cytometry analysis of GFP cells and spleen weight was measured. ...
<p>(A) Rgs2−/− and C57BL/6 wild type mice were injected with 5×10<sup>5</sup> 3LL tumor cells subcut...
<p>Myeloid cells and granulocytic cells from PECs of MOSEC-bearing WT and p47<i><sup>phox−/−</sup></...
<p>A, Tumor incidence from 3 experiments. Equal numbers of sex matched SCID mice were injected s.c. ...